XML 38 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statement of Stockholder's Equity (Deficiency) (USD $)
Total
Preferred Stock
Common Stock
Additional Paid In Capital
Accumulated Deficit
Other Comprehensive Income
Non-Controlled Interest in Subsidiary
Beginning Balance at Dec. 31, 2012      $ 513 $ 12,817,141 $ (17,373,765) $ 188,280   
Beginning Balance, Shares at Dec. 31, 2012     5,133,096         
Common shares issued upon conversion of bond payable-related party and derivative liability at 9.00 per shares, December 2013, Value 174,578    26 2,353,322         
Common shares issued upon conversion of bond payable-related party and derivative liability at 9.00 per shares, December 2013, Shares     261,665         
Common shares issued in payment of notes payable - related party at 6.42 per shares, December 2013, Value 926,386    14 926,372         
Common shares issued in payment of notes payable - related party at 6.42 per shares, December 2013, Shares     144,321         
Common shares issued in payment of note payable - related party at 6.42 per shares, December 2013, Value 1,770,757    28 1,770,730         
Common shares issued in payment of note payable - related party at 6.42 per shares, December 2013, Shares     275,863         
Equity Adjustment for Foreign Currency Translation              (219,470)   
Net Loss          (2,147,361)      
Balance at Dec. 31, 2013 (1,684,170)    581 17,867,565 (19,521,126) (31,190)  
Balance, Shares at Dec. 31, 2013     5,814,945        
To record the recapitalization of Subsidiary in connection with the February 12, 2014 Share Exchange Agreement wherein the DanDrit Biotech USA Inc. (''Parent'') issued 5,814,945 common shares to acquire a 97% interest in DanDrit Biotech A/S (''Subsidiary'')DanDrit Biotech USA Inc., (Formerly Putnam Hills Corp), Value      500 24,500 (104,232)     
To record the recapitalization of Subsidiary in connection with the February 12, 2014 Share Exchange Agreement wherein the DanDrit Biotech USA Inc. (''Parent'') issued 5,814,945 common shares to acquire a 97% interest in DanDrit Biotech A/S (''Subsidiary'')DanDrit Biotech USA Inc., (Formerly Putnam Hills Corp), shares      5,000,000         
Common shares Canceled and returned to authorized in connection with the Share exchange agreement, Value      (440) 440        
Common shares Canceled and returned to authorized in connection with the Share exchange agreement, Shares      (4,400,000)         
To record the issuance of 1,400,000 and 40,000 common shares in connection with the acquisition and offering valued at $5 per share or $7,000,000 nd $200,000, respectfully.      (144) 7,199,856 (7,200,000)     
To record the issuance of 1,400,000 and 40,000 common shares in connection with the acquisition and offering valued at $5 per share or $7,000,000 nd $200,000, respectfully, Shares      1,440,000         
To eliminate the accumulated deficit of Putnam Hills Corp in connection with the recapitalization Share Exchange Agreement, Value        (7,304,232) 7,304,232     
To eliminate the accumulated deficit of Putnam Hills Corp in connection with the recapitalization Share Exchange Agreement, shares                
Equity Adjustment for Foreign Currency Translation 3,354           3,354   
Net Loss (426,054)        (426,054)     
Balance at Mar. 31, 2014 $ (2,347,609)    $ 785 $ 17,788,129 $ (19,947,180) $ (27,836)  
Balance, Shares at Mar. 31, 2014      7,854,945